Harrow (HROW) Other Non-Current Liabilities (2014 - 2024)
Harrow's (HROW) quarterly Other Non-Current Liabilities came in at $2.7 million in Q3 2024, little changed year-on-year from $2.7 million in Q4 2023, and little changed quarter-over-quarter from $2.7 million in Q2 2024.
Harrow (HROW) Other Non-Current Liabilities (2014 - 2024) Analysis & Trends
Harrow's Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $2.7 million for Q3 2024.
- On a quarterly basis, Other Non-Current Liabilities changed 0.0% year-over-year to $2.7 million in Q3 2024; TTM through Sep 2024 was $2.7 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $2.7 million, changed N/A from the prior year.
- Other Non-Current Liabilities held at $2.7 million in Q3 2024 per HROW's latest filing, from $2.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.7 million in Q3 2023 and bottomed at $800000.0 in Q1 2020.
- The 4-year median for Other Non-Current Liabilities is $2.3 million (2023), against an average of $1.8 million.
- Across the five-year window, Other Non-Current Liabilities changed 0.0% in 2020 and rose 19.25% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $800000.0 in 2020, then changed by 0.0% to $800000.0 in 2021, then soared by 239.12% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024.
- Per Business Quant, the three latest HROW Other Non-Current Liabilities figures stand at $2.7 million (Q3 2024), $2.7 million (Q2 2024), and $2.7 million (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 2.28 Mn |
| Mar 31, 2021 | 800,000.00 |
| Dec 31, 2020 | 800,000.00 |
| Sep 30, 2020 | 800,000.00 |
| Jun 30, 2020 | 800,000.00 |
| Mar 31, 2020 | 800,000.00 |
| Dec 31, 2019 | 800,000.00 |
| Sep 30, 2019 | 800,000.00 |
| Jun 30, 2019 | 800,000.00 |
| Mar 31, 2019 | 800,000.00 |
| Dec 31, 2018 | 800,000.00 |
| Sep 30, 2018 | 800,000.00 |
| Jun 30, 2018 | 800,000.00 |
| Mar 31, 2018 | 800,000.00 |